Last update 23 Jan 2025

Satricabtagene autoleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Anti-Claudin18.2-CAR-T cell therapy, CAR-CLD18 T cell therapy, CAR-CLDN18.2 T-Cells
+ [8]
Target
Mechanism
CLDN18.2 inhibitors(Claudin 18.2 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationPRIME (EU), Orphan Drug (EU), Regenerative Medicine Advanced Therapy (US)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastroesophageal junction adenocarcinomaPhase 2
CN
04 Mar 2022
Advanced Gastric AdenocarcinomaPhase 2
US
23 Oct 2020
Advanced Gastric AdenocarcinomaPhase 2
CA
23 Oct 2020
Advanced Gastric AdenocarcinomaPhase 2
CN
23 Oct 2020
Advanced Gastroesophageal Junction AdenocarcinomaPhase 2
CN
23 Oct 2020
Pancreatic CancerPhase 2
CN
23 Oct 2020
Pancreatic CancerPhase 2
CA
23 Oct 2020
Pancreatic CancerPhase 2
US
23 Oct 2020
stomach adenocarcinomaPhase 2
CN
23 Oct 2020
CLDN18.2 positive Pancreatic adenocarcinomaPhase 1
CN
11 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Stomach Cancer
Last line | Third line
-
(lwluqmcerx) = 具有统计学意义上的显著改善。 jnjrfnbmhi (zxfxocoggd )
Met
Positive
30 Dec 2024
研究者选择治疗组(包括紫杉醇、多西他赛、伊立替康、阿帕替尼或纳武利尤单抗)
Phase 1
98
(fksrqqlyqc) = None gxlyhqdrjd (jcdztcssqf )
Positive
03 Jun 2024
(dose-expansion stage)
Phase 1
98
CT041 in pretreated pts with advanced GI cancersCT041 in pretreated pts with advanced GI cancers
(xaspnqcafo) = grade 3 or higher were hematologic toxicity related to lymphodepletion rassqvucsm (agpdffrvjq )
Positive
24 May 2024
CT041 sequential treatment following first-line therapy in gastric cancer (GC)CT041 sequential treatment following first-line therapy in gastric cancer (GC)
Phase 1
24
fzkcefxrot(rjeuidhnuo) = Cytokine release syndrome (CRS) and GI disorders were most reported grade 1 or 2 adverse events xdkxtsmrwl (npqghlforz )
Positive
24 May 2024
Phase 1/2
19
(GC/GEJ)
(vcrbsxurji) = jzfemhgrwt ddauoldrqz (kmzfwiohea )
Positive
19 Jan 2024
(DL3:600×106)
(zooiclcjxs) = kealdsejbd wcrwhzplit (pitfbiadps )
Phase 1/2
14
(cqafscekgi) = Most CRS were grade 1 or 2, and only one patient experienced grade 4 CRS and fully recovered kllxprcjeb (axdmwbswqm )
Positive
02 Jun 2022
Phase 1
37
(fknumvuzxl) = hematologic 100% stebktwrmm (wswyglszhc )
Positive
09 May 2022
Phase 1
37
(tktkiuicgl) = mlythgfigf crlfglgdkr (xntyybnhyo )
Positive
19 Sep 2021
(patients with gastric cancer)
(pmhzzblfoy) = ufycbfttpo igvhhcayho (ebfkgdthdk, 37.2 - 75.5)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free